Welcome to the UPF Digital Repository

Available and affordable complementary treatments for COVID-19: From hypothesis to pilot studies and the need for implementation

Show simple item record

dc.contributor.author Bousquet, Jean
dc.contributor.author Haahtela, Tari
dc.contributor.author Blain, Hubert
dc.contributor.author Czarlewski, Wienczyslawa
dc.contributor.author Zuberbier, Torsten
dc.contributor.author Bedbrook, Anna
dc.contributor.author Cruz, Alvaro A.
dc.contributor.author Fonseca, Joao A.
dc.contributor.author Klimek, Ludger
dc.contributor.author Kuna, Piotr
dc.contributor.author Samolinski, Boleslaw
dc.contributor.author Valiulis, Arunas
dc.contributor.author Lemaire, Antoine
dc.contributor.author Antó i Boqué, Josep Maria
dc.date.accessioned 2022-05-02T06:08:37Z
dc.date.available 2022-05-02T06:08:37Z
dc.date.issued 2022
dc.identifier.citation Bousquet J, Haahtela T, Blain H, Czarlewski W, Zuberbier T, Bedbrook A, Cruz AA, Fonseca JA, Klimek L, Kuna P, Samolinski B, Valiulis A, Lemaire A, Anto JM. Available and affordable complementary treatments for COVID-19: From hypothesis to pilot studies and the need for implementation. Clin Transl Allergy. 2022 Mar;12(3):e12127. DOI: 10.1002/clt2.12127
dc.identifier.issn 2045-7022
dc.identifier.uri http://hdl.handle.net/10230/52951
dc.description.abstract Vaccination is a highly effective preventive measure against COVID-19. However, complementary treatments are needed to better control the disease. Fermented vegetables and spices, agonists of the antioxidant transcription factor nuclear factor (erythroid-derived 2)-like 2 (Nrf2) and TRPA1/V1 channels (Transient Receptor Potential Ankyrin 1 and Vanillin 1), may help in the control of COVID-19. Some preliminary clinical trials suggest that curcumin (spice) can prevent some of the COVID-19 symptoms. Before any conclusion can be drawn and these treatments recommended for COVID-19, the data warrant confirmation. In particular, the benefits of the foods need to be assessed in more patients, through research studies and large trials employing a double-blind, placebo-controlled design.
dc.format.mimetype application/pdf
dc.language.iso eng
dc.publisher Wiley
dc.relation.ispartof Clin Transl Allergy. 2022 Mar;12(3):e12127
dc.rights © 2022 The Authors. Clinical and Translational Allergy published by John Wiley & Sons Ltd on behalf of European Academy of Allergy and Clinical Immunology. This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
dc.rights.uri http://creativecommons.org/licenses/by/4.0/
dc.title Available and affordable complementary treatments for COVID-19: From hypothesis to pilot studies and the need for implementation
dc.type info:eu-repo/semantics/article
dc.identifier.doi http://dx.doi.org/10.1002/clt2.12127
dc.subject.keyword COVID-19
dc.subject.keyword Nrf2
dc.subject.keyword TRP channel
dc.subject.keyword Broccoli
dc.subject.keyword Curcumin
dc.rights.accessRights info:eu-repo/semantics/openAccess
dc.type.version info:eu-repo/semantics/publishedVersion

Thumbnail

This item appears in the following Collection(s)

Show simple item record

Search DSpace


Advanced Search

Browse

My Account

Statistics

Compliant to Partaking